Shares in Biogen plummeted yesterday after the biotechnology giant said that its experimental Alzheimer’s drug was unlikely to be effective and that it was halting its research, in another setback to efforts to find a therapy for the neurodegenerative ailment.
Shares dropped by as much as 29 per cent in heavy trading, knocking about $18 billion off the company’s market value and marking its biggest intraday stock drop since 2008.
The US-based company said...
Subscribe from just €1 for the first month!
All Digital Access + eReader
Unlimited Access for 1 Month
Then €19.99 a month after the offer period.
€149 For the 1st Year
Unlimited Access for 1 Year
90 Day Pass
Unlimited Access for 2 Years
Get a Business Account for you and your team